CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.

@article{Camoratto1997CEP751IT,
  title={CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.},
  author={Anna Marie Camoratto and Jitesh P. Jani and Thelma S. Angeles and Anna C Maroney and Charlotte Sanders and Chikara Murakata and Nicola T Neff and Joshua L. Vaught and John T Isaacs and Craig A Dionne},
  journal={International journal of cancer},
  year={1997},
  volume={72 4},
  pages={673-9}
}
The present report describes the in vitro and in vivo profile of CEP-751, a novel receptor tyrosine kinase inhibitor. CEP-751 at 100 nM inhibits the receptor tyrosine kinase activity of the neurotrophin receptors trkA, trkB and trkC. CEP-751 has no effect on activity of receptors for EGF, IGF-I, insulin or on erbB2; inhibition of receptors for PDGF and bFGF was observed but occurred with lesser potency than inhibition of trk. CEP-751 exhibited anti-tumor efficacy against tumors derived from… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…